Bradley Glover
Chief Operating Officer chez IMUGENE LIMITED
Fortune : 183 672 $ au 31/03/2024
Profil
Bradley Glover is currently the Chief Operating Officer at Imugene Ltd.
He previously worked as the Vice President of Corporate Development at Kite Pharma, Inc. and as the Chief Technology Officer and Executive Vice President at Celularity, Inc. (United States).
He also served as the Chief Operating Officer and Executive Vice President at Celularity, Inc. from 2021 to 2023.
Dr. Glover received his undergraduate degree from the University of California San Diego, his doctorate from the University of Colorado, and his MBA from the Rady School of Management at UC San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CELULARITY INC. CLASS A
0,16% | 13/04/2023 | 35 119 ( 0,16% ) | 183 672 $ | 31/03/2024 |
Postes actifs de Bradley Glover
| Sociétés | Poste | Début |
|---|---|---|
| IMUGENE LIMITED | Chief Operating Officer | 21/08/2023 |
Anciens postes connus de Bradley Glover
| Sociétés | Poste | Fin |
|---|---|---|
| CELULARITY INC. | Chief Operating Officer | 31/05/2023 |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Chief Tech/Sci/R&D Officer | - |
| KITE PHARMA INC | Corporate Officer/Principal | - |
Formation de Bradley Glover
| University of California San Diego | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
| Rady School of Management at UC San Diego | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMUGENE LIMITED | Health Technology |
| CELULARITY INC. | Commercial Services |
| Entreprise privées | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Celularity, Inc. (United States)
Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Commercial Services |
